These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1227 related articles for article (PubMed ID: 33648563)

  • 41. Decision support system to evaluate ventilation in the acute respiratory distress syndrome (DeVENT study)-trial protocol.
    Patel B; Mumby S; Johnson N; Falaschetti E; Hansen J; Adcock I; McAuley D; Takata M; Karbing DS; Jabaudon M; Schellengowski P; Rees SE;
    Trials; 2022 Jan; 23(1):47. PubMed ID: 35039050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.
    Aman J; Duijvelaar E; Botros L; Kianzad A; Schippers JR; Smeele PJ; Azhang S; Bartelink IH; Bayoumy AA; Bet PM; Boersma W; Bonta PI; Boomars KAT; Bos LDJ; van Bragt JJMH; Braunstahl GJ; Celant LR; Eger KAB; Geelhoed JJM; van Glabbeek YLE; Grotjohan HP; Hagens LA; Happe CM; Hazes BD; Heunks LMA; van den Heuvel M; Hoefsloot W; Hoek RJA; Hoekstra R; Hofstee HMA; Juffermans NP; Kemper EM; Kos R; Kunst PWA; Lammers A; van der Lee I; van der Lee EL; Maitland-van der Zee AH; Mau Asam PFM; Mieras A; Muller M; Neefjes ECW; Nossent EJ; Oswald LMA; Overbeek MJ; Pamplona CC; Paternotte N; Pronk N; de Raaf MA; van Raaij BFM; Reijrink M; Schultz MJ; Serpa Neto A; Slob EMA; Smeenk FWJM; Smit MR; Smits AJ; Stalenhoef JE; Tuinman PR; Vanhove ALEM; Wessels JN; van Wezenbeek JCC; Vonk Noordegraaf A; de Man FS; Bogaard HJ
    Lancet Respir Med; 2021 Sep; 9(9):957-968. PubMed ID: 34147142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
    Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
    Front Immunol; 2022; 13():932360. PubMed ID: 35860245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.
    Ali S; Shalim E; Farhan F; Anjum F; Ali A; Uddin SM; Shahab F; Haider M; Ahmed I; Ali MR; Khan S; Rao S; Guriro K; Elahi S; Ali M; Mushtaq T; Sayeed MA; Muhaymin SM; Luxmi S; Saifullah ; Qureshi S
    Trials; 2022 Nov; 23(1):932. PubMed ID: 36348476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients': a retrospective, multi-centric cohort study.
    Salehi M; Barkhori Mehni M; Akbarian M; Fattah Ghazi S; Khajavi Rad N; Moradi Moghaddam O; Jamali Moghaddam S; Hosseinzadeh Emam M; Abtahi SH; Moradi M; Ghiasvand F
    Eur J Med Res; 2022 Feb; 27(1):18. PubMed ID: 35115056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of patients with COVID-19 acute respiratory distress syndrome requiring invasive mechanical ventilation admitted to an intensive care unit in South Africa.
    Arnold-Day C; Van Zyl-Smit RN; Joubert IA; Thomson DA; Fredericks DL; Miller MGA; Michell WL; Semple PL; Piercy JL
    S Afr Med J; 2022 Feb; 112(1):13516. PubMed ID: 35140002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; McAuley DF; O'Kane C
    Trials; 2022 May; 23(1):401. PubMed ID: 35562778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial.
    Labro G; Tubach F; Belin L; Dubost JL; Osman D; Muller G; Quenot JP; Da Silva D; Zarka J; Turpin M; Mayaux J; Lamer C; Doyen D; Chevrel G; Plantefeve G; Demeret S; Piton G; Manzon C; Ochin E; Gaillard R; Dautzenberg B; Baldacini M; Lebbah S; Miyara M; Pineton de Chambrun M; Amoura Z; Combes A;
    Intensive Care Med; 2022 Jul; 48(7):876-887. PubMed ID: 35676335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Longitudinal changes in compliance, oxygenation and ventilatory ratio in COVID-19 versus non-COVID-19 pulmonary acute respiratory distress syndrome.
    Beloncle F; Studer A; Seegers V; Richard JC; Desprez C; Fage N; Merdji H; Pavlovsky B; Helms J; Cunat S; Mortaza S; Demiselle J; Brochard L; Mercat A; Meziani F
    Crit Care; 2021 Jul; 25(1):248. PubMed ID: 34266454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)-study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2022 Jan; 23(1):35. PubMed ID: 35033182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dead space estimates may not be independently associated with 28-day mortality in COVID-19 ARDS.
    Morales-Quinteros L; Neto AS; Artigas A; Blanch L; Botta M; Kaufman DA; Schultz MJ; Tsonas AM; Paulus F; Bos LD;
    Crit Care; 2021 May; 25(1):171. PubMed ID: 34001222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.
    Tabarsi P; Barati S; Jamaati H; Haseli S; Marjani M; Moniri A; Abtahian Z; Dastan A; Yousefian S; Eskandari R; Saffaei A; Monjazebi F; Vahedi A; Dastan F
    Int Immunopharmacol; 2021 Jan; 90():107205. PubMed ID: 33214093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.
    Rein L; Calero K; Shah R; Ojielo C; Hudock KM; Lodhi S; Sadaka F; Bellam S; Palma C; Hager DN; Daniel J; Schaub R; O'Hayer K; Theodoropoulos NM
    Crit Care Med; 2022 Dec; 50(12):1701-1713. PubMed ID: 36226977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol.
    Mera-Cordero F; Bonet-Monne S; Almeda-Ortega J; García-Sangenís A; Cunillera-Puèrtolas O; Contreras-Martos S; Alvarez-Muñoz G; Monfà R; Balanzo-Joué M; Morros R; Salvador-Gonzalez B
    Trials; 2022 Jan; 23(1):19. PubMed ID: 34991703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome.
    Perkins GD; Gates S; Lamb SE; McCabe C; Young D; Gao F
    Trials; 2011 May; 12():113. PubMed ID: 21554679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lescure FX; Honda H; Fowler RA; Lazar JS; Shi G; Wung P; Patel N; Hagino O;
    Lancet Respir Med; 2021 May; 9(5):522-532. PubMed ID: 33676590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.
    Nickols NG; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Might M; Goldstein DB; Wang X; Ramoni R; Myrie K; Tran S; Ghayouri L; Tsai S; Geelhoed M; Makarov D; Becker DJ; Tsay JC; Diamond M; George A; Al-Ajam M; Belligund P; Montgomery RB; Mostaghel EA; Sulpizio C; Mi Z; Dematt E; Tadalan J; Norman LE; Briones D; Clise CE; Taylor ZW; Huminik JR; Biswas K; Rettig MB
    Trials; 2021 Jul; 22(1):431. PubMed ID: 34225789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.
    Misset B; Hoste E; Donneau AF; Grimaldi D; Meyfroidt G; Moutschen M; Compernolle V; Gothot A; Desmecht D; Garigliany M; Najdovski T; Laterre PF
    BMC Pulm Med; 2020 Dec; 20(1):317. PubMed ID: 33287790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improved outcomes over time for adult COVID-19 patients with acute respiratory distress syndrome or acute respiratory failure.
    Yeates EO; Nahmias J; Chinn J; Sullivan B; Stopenski S; Amin AN; Nguyen NT
    PLoS One; 2021; 16(6):e0253767. PubMed ID: 34170950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolonged Intermittent Renal Replacement Therapy for Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome.
    Ramirez-Sandoval JC; Gaytan-Arocha JE; Xolalpa-Chávez P; Mejia-Vilet JM; Arvizu-Hernandez M; Rivero-Sigarroa E; Torruco-Sotelo C; Correa-Rotter R; Vega-Vega O
    Blood Purif; 2021; 50(3):355-363. PubMed ID: 33105136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.